RT Book, Section
A1 Nolin, Thomas D.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1155626473
T1 Drug-Induced Kidney Disease
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1155626473
RD 2024/04/24
AB Content  UpdateAugust  7,  2018Nephrotoxic  Potential  of  Novel  Anticancer  Immunotherapies:  Several  novel  anticancer  immunotherapies  have  been  associated  with  development  of  nephrotoxicity  -  the  checkpoint  inhibitors  (CPIs)  ipilimumab,  pembrolizumab,  and  nivolumab  and  the  chimeric  antigen  receptor  therapy  (CAR-T)  products  tisagenlecleucel  and  axicabtagene  ciloleucel.  Acute  kidney  injury  (AKI)  may  occur  3  to  16  months  after  CPI  exposure,  which  makes  extended  renal  function  monitoring  critical  for  detection  and  treatment.  CAR-T  is  associated  with  cytokine  release  syndrome,  tumor  lysis  syndrome,  and  electrolyte  abnormalities.  Given  the  increasing  use  of  these  novel  agents,  collaboration  among  oncologists,  nephrologists,  pharmacists,  and  other  clinicians  is  vital  to  ensure  appropriate  agent-specific  monitoring  and  management  of  renal  adverse  effects  while  maintaining  maximum  anticancer  efficacy.